← Back to Search

Other

KVA12123 + Pembrolizumab for Cancer

Phase 1 & 2
Recruiting
Research Sponsored by Kineta Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be at least 18 years of age at the time of consent
Has consented to the collection of archival tissue prior to study treatment initiation
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights

Study Summary

This trial is testing a new drug to see if it's safe and effective in treating advanced solid tumors. Participants will visit the site regularly and receive treatments, with tests to check safety and cancer progression.

Who is the study for?
Adults with advanced solid tumors that have worsened or didn't respond to standard treatments can join this trial. They must be in relatively good health, able to follow the study plan, and not pregnant. People with certain infections like HIV or hepatitis B/C can join if their condition is under control. Those who've had recent cancer treatments or major surgeries, active lung disease, severe allergies, or are on high-dose steroids cannot participate.Check my eligibility
What is being tested?
The trial tests KVA12123 alone and combined with Pembrolizumab for safety and proper dosage against various advanced cancers. Participants will receive KVA12123 every two weeks and Pembrolizumab every six weeks while undergoing regular scans, blood tests, physical exams, and heart function tests to monitor treatment effects.See study design
What are the potential side effects?
Potential side effects include reactions at the injection site, fatigue, changes in blood counts leading to increased infection risk or bleeding problems. There may also be immune-related issues affecting organs like the lungs (pneumonitis), liver (hepatitis), intestines (colitis), hormone glands (endocrinopathies) among others.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I have agreed to provide samples of my previous biopsy or surgery for the study.
Select...
I am fully active or can carry out light work.
Select...
My thyroid function is normal or I have stable hypothyroidism with treatment.
Select...
I stopped taking targeted therapy or similar drugs 2 weeks ago.
Select...
My advanced cancer did not respond to standard treatments and cannot be cured.
Select...
I am HIV positive, on ART, and my HIV is well-controlled.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
AEs related to study drug
Adverse Events
Recommended Phase 2 dose (RP2D) or maximum tolerated dose (MTD)
Secondary outcome measures
Concentration of anti-KVA12123 antibodies in serum
Number of participants with complete response following treatment with KVA12123
Number of participants with complete response following treatment with KVA12123 plus pembrolizumab
+13 more

Trial Design

4Treatment groups
Experimental Treatment
Group I: KVA12123 Plus Pembrolizumab Dose ExpansionExperimental Treatment1 Intervention
Part D will consist of dose expansion with KVA12123 administered at the RP2D in combination with a fixed dose of pembrolizumab.
Group II: KVA12123 Plus Pembrolizumab Dose EscalationExperimental Treatment1 Intervention
Part B will consist of dose escalation with KVA12123 administered in combination with a fixed dose of pembrolizumab.
Group III: KVA12123 Monotherapy Dose ExpansionExperimental Treatment1 Intervention
Part C will consist of dose expansion with KVA12123 administered as a single agent at the RP2D in participants with advanced solid tumors.
Group IV: KVA12123 Monotherapy Dose EscalationExperimental Treatment1 Intervention
Part A will consist of dose escalation with KVA12123 administered as a single agent in participants with advanced solid tumors.

Find a Location

Who is running the clinical trial?

Merck Sharp & Dohme LLCIndustry Sponsor
3,906 Previous Clinical Trials
5,064,404 Total Patients Enrolled
Kineta Inc.Lead Sponsor
3 Previous Clinical Trials
80 Total Patients Enrolled
Thierry Guillaudeux, PhDStudy DirectorKineta Inc.

Media Library

KVA12123 Treatment (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05708950 — Phase 1 & 2
Cancer Research Study Groups: KVA12123 Monotherapy Dose Expansion, KVA12123 Monotherapy Dose Escalation, KVA12123 Plus Pembrolizumab Dose Escalation, KVA12123 Plus Pembrolizumab Dose Expansion
Cancer Clinical Trial 2023: KVA12123 Treatment Highlights & Side Effects. Trial Name: NCT05708950 — Phase 1 & 2
KVA12123 Treatment (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05708950 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still opportunities to partake in this study?

"Affirmative, the study is currently seeking enrollees. The trial was initially posted on March 3rd 2023 and has since been updated on the same date. It requires 314 individuals to be recruited from 2 different medical facilities."

Answered by AI

What is the aggregate amount of participants involved in this experiment?

"Affirmative. The clinical trial's webpage on clinicaltrials.gov attests to its active recruitment of participants, which began on March 3rd 2023 and was last updated the same day. It is currently looking for 314 individuals from 2 separate sites."

Answered by AI

What is the fundamental purpose of this trial?

"This clinical experiment will be assessing the RP2D or MTD of a drug over one year as its primary outcome. Additionally, secondary goals are to measure partial response in patients, peak serum concentration time (tmax), and change from baseline anti-KVA12123 antibodies in serum concentrations."

Answered by AI

Who else is applying?

What site did they apply to?
Sarah Cannon Research Institute at Florida Cancer Specialists
What portion of applicants met pre-screening criteria?
Met criteria
~21 spots leftby Jun 2024